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Effect of sugammadex on chest radiographic abnormality in the early postoperative
period after video-assisted thoracoscopic lobectomy
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Background/aim: Sugammadex, which offsets the effects of neuromuscular blocking agents (NMBs), has advantages over traditional
reversal agents like pyridostigmine, as it enables fast and reliable recovery from neuromuscular blockade. This study compared the
incidence of early postoperative chest radiographic abnormalities (CRA) between sugammadex (group S) and pyridostigmine (group
P) following video-assisted thoracoscopic (VAT) lobectomy for lung cancer.
Materials and methods: We performed a retrospective cohort analysis by reviewing the medical records of patients who underwent
VAT lobectomy at a single university medical center. We defined the early postoperative CRA as a characteristic appearance on chest
radiograph up to 2 days after surgery. Arterial blood gas analysis (ABGA), surgical time, anaesthesia time, extubation time, and the total
dose of rocuronium were analysed. Postoperative nausea and vomiting (PONV) and pain scores were observed until 2 days after surgery.
Results: A total of 257 patients underwent VAT lobectomy during the study period; 159 were included in the final analysis. Ninety
patients received sugammadex while 69 received pyridostigmine. The incidence of early postoperative atelectasis was significantly lower
in group S than in group P (26.7%, 95% CI: 17.5%‒35.8% and 43.5%, 95% CI: 31.8%‒55.2%, respectively, P = 0.013). The median dose
of rocuronium was higher in group S than in group P (120 mg vs. 90 mg, P < 0.001). ABGA, extubation time, and PONV were similar
in both groups.
Conclusion: Sugammadex decreased the incidence of CRA in the early postoperative period despite higher NMB consumption.
Key words: Thoracic radiography, postoperative complications, sugammadex, anticholinesterases, video-assisted thoracic surgery

1. Introduction
Video-assisted thoracoscopic surgery (VATS) enables
rapid postoperative recovery and reduces the incidence
of postoperative pain and other complications
compared to conventional thoracotomy [1–3]. Singleport VATS with a minimal incision of 3–5 cm has been
advocated as the surgical method for lung lobectomy,
a currently available technique in lung cancer surgery
[4–7]. It offers several advantages over 3-port VATS,
including less postoperative pain and a better cosmetic
result [8]. However, this surgical procedure requires
delicate techniques within a limited surgical field,
a profound neuromuscular block is essential and
requires a higher dose of NMB use. Consequently, it
is important to be sure about enhanced recovery from
NMBs to reduce the risk of respiratory complications
[9,10].

The reversal agent with anticholinesterase plays
a limited role when a high dose of muscle relaxant
is used [11–14]. Sugammadex binds to steroidal
nondepolarizing muscle relaxants in a 1:1 ratio,
completely antagonizes its neuromuscular blocking
effect, and is excreted through the kidneys as inactivated
form. Depending on its dose, sugammadex effectively
reverses neuromuscular blocking agents induced
by rocuronium even in the presence of profound
neuromuscular block [15].
Therefore, we hypothesised that using sugammadex
as a reversal agent could enhance the ability of pulmonary
rehabilitation compared to using anticholinesterase. To
prove this hypothesis, we compared early postoperative
respiratory abnormalities that appeared on chest
radiography between using 2 different reversal agents
after the single-port VAT lobectomy.
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2. Materials and methods
2.1. Study design and setting
This study was approved by the institutional review board
(KUGH15280-001) and we performed a single-center
retrospective cohort study in a university teaching hospital.
Between January 2013 and August 2015, 257 patients who
underwent a single-port VAT lobectomy at the Korea
University Medical Center Guro Hospital (Seoul, Republic
of Korea) were screened for eligibility. Since our institution
has started to use sugammadex in late 2013, we included
the patients who underwent single-port VAT lobectomy
for about 1 year before and after 2014. The recruited
patients had been managed by 3 anesthesiologists who
were specialists in thoracic anesthesia and the operation
was performed by 1 thoracic surgeon. Using the internal
hospital code corresponding to a single-port VAT
lobectomy, the hospital medical record management team
provided the data from the electronic medical system.
2.2. Patient population
We included patients who met the following criteria: aged
over 19 years, elective lung lobectomy or bilobectomy
using a single-port VATS, and American Society of
Anesthesiologists (ASA) physical status class I or II. We
excluded patients with previous history of thoracic surgery,
surgery other than single-port VATS, surgery other
than lung cancers, preexisting respiratory/abdominal
muscle weakness or neuromuscular diseases, congestive
heart failure, asthma, chronic obstructive pulmonary
disease or emphysema (other than stage I), other chronic
pulmonary diseases that could affect postoperative lung
function (for example: pneumonia caused from bacteria
or virus, lung abscess), end-stage renal disease on
dialysis, diagnosed with Child-Pugh classification A or
over hepatic impairment, and the use of neuromuscular
blocking agents other than rocuronium during anesthesia,
the case of conversion to thoracotomy during surgery,
and patients with unconfirmed chest radiography pre or
postoperatively. Of the 257 patients reviewed, we excluded
98 patients in accordance with the exclusion criteria as
detailed in Figure 1. One hundred and fifty-nine patients
were included in the final analysis. Patients who received
sugammadex at the end of anesthesia were classified as
group S (n = 90), and those who received pyridostigmine
were classified as group P (n = 69).
Anesthesia was induced using propofol or pentothal
sodium and maintained using sevoflurane or desflurane
with N2O. With invasive monitoring for arterial and
central venous pressure, one-lung ventilation (OLV)
was achieved using a double-lumen endotracheal tube
or a single-lumen endotracheal tube with a bronchial
blocker. Continuous infusion of remifentanil or bolus of
fentanyl was administrated when required. Rocuronium
(EsmeronTM Inj., N.V. Organon, Oss, the Netherlands)

was the sole agent used for facilitating endotracheal
intubation and muscle relaxation during anesthesia. A
minimal intraoperative fluid management strategy was
applied to all patients. Mechanical ventilation was applied
during anesthesia as follows: before OLV, a tidal volume
(TV) of 8 mL/kg, respiration rate (RR) of 12 cycles/min,
inspiration to expiration ratio (I:E) of 1:2, with or without
5~10 cmH2O positive end-expiratory pressure (PEEP),
and 50% FiO2 with N2O; during OLV, a TV of 6~7 mL/kg,
RR of 15~16 cycles/min, I:E of 1:2, with or without 5~10
cmH2O PEEP, and 100% FiO2. The alveolar recruitment
maneuver was performed in all patients at the end of
surgery and 2-lung ventilation was restored. To reverse
the effects of NMBs, sugammadex (BridionTM Inj., N.V.
Organon, the Netherlands) or pyridostigmine (PyrinulTM
Inj., Myungmoon Pharm., Seoul, Republic of Korea) and
glycopyrrolate (MobinulTM Inj., Myungmoon Pharm.,
Seoul, Republic of Korea) were administered. After
emergence from anesthesia, the patient was extubated and
transferred to the intensive care unit (ICU). Standardized
postoperative management was applied to all patients
including semi-Fowler’s position, active coughing and
deep breathing encouragement, periodic position changes
for bronchial toilet, chest percussions when required,
minimizing oxygen administration as possible, and pain
control principles.
2.3. Data collection
Provided medical records were reviewed separately by
2 investigators and validated by 1 other investigator. If
there was a discordant between the collected data, three
investigators looked up the provided medical records and a
decision was made after in-depth discussion. Information
on age, sex, height, body weight, ASA physical status
class, smoking history, medical histories of hypertension,
diabetes, asthma, and chronic obstructive lung disease,
including emphysema, preoperative pulmonary function
tests (forced expiratory volume in 1 s [FEV1], forced vital
capacity [FVC], and diffusing capacity of the lung for
carbon monoxide [DLCO]), and the types of surgery were
collected. Preoperative pulmonary symptoms including
cough, sputum, and dyspnea were also investigated.
During surgery, anesthetic factors were also gathered,
including durations of anesthesia and surgery, providing
1-lung ventilation, intraoperative mechanical ventilator
settings, arterial blood gas analysis (ABGA) results, total
dose of rocuronium used, whether or not sugammadex was
used and its dose, and total fluid administered, including
crystalloid and colloid. Using blood products during
the operation was also counted separately. Postoperative
chest radiography findings from the day of operation to
2 postoperative days were also investigated. Postoperative
pain scores on a 10-point numerical rating scale (NRS)
were used in the surgical ICU and general ward. Reported
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VATS lobectomy or bi-lobectomy (N=257)
• Jan 2013 to Aug 2015
• ASA I, II
• Age over 20 years old
• Surgery performed by one surgeon
• Single-port VATS
Excluded (N=95)
• Diagnosed otherwise than lung cancer (N=16)
• Not a single-port VATS (N=13)
• Converted to open thoracotomy (N=4)
• Severe lung disease (N=5)
• Severe systemic disease; ESRD, LC (N=8)
• Neuromuscular blocker other than rocuronium (N=41)
• Previous lung surgery (N=8)
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Database
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Single-port VATS lobectomy, lung cancer.
(N=162)
Excluded (N=3)
• Incomplete data (N=3)

Included in statistical analysis (N=159)

Patients received “Pyridostigmine”
(Group P, N=69)

Patients received “Sugammadex”
(Group S, N=90)

Figure 1. Flow diagram showing patient inclusion, exclusion, and statistical analysis. All patient data were collected by medical record
review. VATS: video-assisted thoracic surgery; ASA: American Society of Anesthesiologists: ASA is the name of organization, using
American style typing. Physical status classifications; ESRD: end-stage renal disease; LC: liver cirrhosis.

postoperative nausea and vomiting (PONV) were also
counted as followed from the nursing care records.
2.4. Outcome measurement and definitions
The primary outcome was the incidence of early postoperative
chest radiographic abnormalities (CRA). Early postoperative
CRA on aeration was defined as the chest radiologists’
report during postoperative 2 days, including pneumonic
infiltrations, lobar, segmental, and subsegmental atelectasis
confirmed by a certified radiologist on postoperative chest
radiography. If chest radiography report was not available
even though the patient had taken chest radiography, we
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excluded the case. Other chest radiographic findings also
followed from the report of the chest radiologist. Pneumonia
was defined when the patient presented pneumonic
infiltration on chest radiography with clinical symptoms or
laboratory findings indicating pneumonia, including a fever
over 38 °C, purulent sputum that was not reported before
surgery, leukocytosis that was not explained by another
cause except lung infection. With clinical findings, pleural
effusion and hemothorax were also recorded when they were
presented simultaneously on the chest radiography report
and medical records. The secondary outcome was identifying
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the parameters that could be a cause of early postoperative
CRA among the collected variables.
2.5. Statistical analysis
We used IBM SPSS Statistics for Windows (Version 23.0,
IBM Corp., Armonk, NY, USA, 2015) and R software
3.5.2 (R Development Core Team, Vienna, Austria, 2018).
All data were coded with numerical values and titles of
variables were also named with coded characters to blind
the statistician. Before statistical analysis, missing data
analysis was performed. For the variable that had missing
values over 5% of cases, we inspected those missing values
that occurred at random; then imputation was applied
with the univariate imputation method of classification
and regression trees, maximal iteration was set at 250, the
number of multiple imputations was 5 [16]. We assessed
the imputed values with an overimputation diagnostic plot
[17]. Otherwise, we performed a complete case analysis for
variables with missing values of less than 5%. Intraoperative
ABGA checked approximately a half an hour after
establishing 1-lung ventilation for thoracoscopic surgery
presented a 9.7% missing rate. The missing pattern of this
variable was not related to the patients’ characteristics; we
performed missing value imputation as planned. After
imputation, cross-validation was adequate.
For continuous variables, a normality test was
performed with the Shapiro–Wilk test. If a variable violated
the normality, nonparametric methods were applied.
Student’s t-test, Mann–Whitney U test, one-way ANOVA
with 1 repeated factor, chi-square test, or Fisher’s exact test
were performed depending on the type of variables. In
the one-way ANOVA with 1 repeated factor, a sphericity
test was performed using the Mauchly’s method. If the
sphericity assumption was violated, Greenhouse–Geisser
correction was performed. The ANOVA results were
interpreted by verifying the interaction between variables.
The primary outcome variable, early postoperative CRA,
was evaluated with a z-test to compare the estimated
incidence rate. Multiple logistic regression was performed
to investigate the possible effects of demographic data on
early postoperative CRA. The variables were determined
by a backward stepwise selection method, tested with loglikelihood estimation. Correlation analysis of the selected
variables was performed to evaluate the interaction and
collinearity. The final model was tested with HosmerLemeshow statistics for the goodness-of-fit and a visual
check of Cook’s distance. Bootstrapping was used with
1000 numbers of simple sampling methods. The fitted
model was presented with an odds ratio (OR) and its 95%
CI.
Results were presented as mean ± SD, median (IQR)
or number (percentile) for the measured data, mean (95%
confidence intervals [CI]), or number (ratio [95% CI]) for
the estimated values. Statistical results were presented with

2-sided P values and corresponding effect sizes. P value of
less than 0.05 was considered statistically significant.
3. Results
All preoperative parameters were not statistically different
between the 2 groups, except diabetes mellitus prevalence.
The prevalence of diabetes mellitus in group S was 20.0%,
higher than in group P with small effect size (5.8%, P =
0.011, Crémer’s V = 0.20, Table 1). Among intraoperative
parameters, there were no statistical differences between
groups with respect to N2O used, fluid administered
volume, anesthesia time, operation time, extubation time,
and units of transfusion (Table 2). Group S received a
higher dose of rocuronium (120.0 mg [100.0–140.0 mg])
compared to group P with moderate effect size (90.0 mg
[70.0–107.5 mg], P < 0.001, r = 0.55). The median dose
of pyridostigmine in group P was 10 mg (10–10 mg), 5
patients in group P received 15 mg of pyridostigmine
for NMBs reversal, otherwise, 10 mg of pyridostigmine
were administered. Patients in group S received 2.08 mg/
kg (2.01–2.20 mg/kg), ranging from 1.38 to 3.77 mg/kg.
Expired tidal volume during 1-lung ventilation was not
different between groups (339.6 ± 52.8 mL vs. 350.0 ± 60.8
mL for groups P and S, respectively, P = 0.223, Cohen’s d
= 0.20). The median scores of maximum pain measured
using NRS were not different between groups (3.0 [3.0–5.0]
vs. 3.0 [3.0–4.0]) for groups P and S, respectively, P = 0.734,
r = 0.03). PONV incidence was not statistically different.
Overall incidence of early postoperative CRA was
29.4% (95% CI: 22.6%–25.2%, Table 3). The incidence in
group S was moderately lower compared to group P (26.7%
[95% CI: 17.5%–35.8%] and 43.5% [95% CI: 31.8%–55.2%]
in groups S and P, respectively, P = 0.013, Cohen’s h = 0.35,
Figure 2). These were mainly observed at operated lung
side in both groups, not different between groups (P =
0.359, Crémer’s V = 0.14). Pleural effusion was developed
similarly in both groups (42.0% vs. 36.7% for groups P and
S, respectively, P = 0.245, Crémer’s V = 0.11). Hemothorax,
when counted separately from others, was observed only
in group P (4.3% vs. 0.0% for groups P and S, respectively,
P = 0.080, Crémer’s V = 0.11). No patients presented overt
pneumonia with symptoms and signs.
Parameters related to early postoperative CRA were
evaluated through binary logistic regression (Table 4). In
the case of using sugammadex for neuromuscular blocker
reversal, CRA decreased significantly (odds ratio = 0.273,
95% CI: 0.112–0.669, P = 0.005). As age increment by 1
year, the odds of CRA have increased 1.078 folds (95% CI:
1.021–1.137, P = 0.006). Higher BMI had a significant OR
for CRA (1.161, 95% CI: 1.017–1.324, P = 0.027). Female
sex, current smoking, hypertension, DLCO%, and PONV
were included in the final model, and they presented
insignificant results after bootstrapping.
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Table 1. Preoperative patient characteristics.
Parameters

Group P (n = 69)

Group S (n = 90)

Mean difference

P value

Effect size

59.7 ± 9.2

59.5 ± 9.5

0.2 (–3–3.5)

0.888

0.03

Body mass index (kg/m )

23.14 ± 2.99

23.16 ± 3.23

–0.02 (–1.11–1.07)

0.973

0.01

No. of female

19 (27.5%)

30 (33.3%)

-

0.490

0.06

Current smoking

15 (21.7%)

16 (17.8%)

-

0.551

0.05

Hypertension

26 (37.7%)

33 (36.7%)

-

>0.99

0.01

Diabetes mellitus

4 (5.8%)

18 (20.0%)

-

0.011*

0.20

Chronic lung disease

5 (7.2%)

3 (3.3%)

-

0.295

0.09

Cough

11 (15.9%)

11 (12.2%)

-

0.644

0.05

Sputum

9 (13.0%)

10 (11.1%)

-

0.807

0.03

Dyspnoea

2 (2.9%)

2 (2.2%)

-

>0.99

0.02

FVC%

88.9 ± 13.9

88.5 ± 10.9

0.3 (–4.1–4.7)

0.882

0.03

FEV1%

85 ± 16.8

84.3 ± 13.2

0.7 (–4.6–6)

0.784

0.05

5.8 (–0.8–12.3)

0.084

0.31

-

0.553

0.21

Age (years)
2

Preoperative chest
symptoms

DLCO%

Site of operation

87.6 ± 19.6

81.8 ± 17.8

RUL

16 (23.2%)

21 (23.3%)

RML

5 (7.2%)

4 (4.4%)

RLL

18 (26.1%)

23 (25.6%)

RUL&RML

0 (0%)

3 (3.3%)

RUL&RLL

0 (0%)

2 (2.2%)

RML&RLL

5 (7.2%)

3 (3.3%)

LUL

12 (17.4%)

21 (23.3%)

LLL

13 (18.8%)

13 (14.4%)

Data are presented as mean ± standard deviation or number of patients (percentile). Mean differences are presented with a 95%
confidence interval. Group P: patients who received pyridostigmine as the reversal agent. Group S: patients who received sugammadex
as the reversal agent. FVC%: percentile of functional vital capacity; FEV1%: percentile of forced expiratory volume in 1 s; RUL: right
upper lobe; RML right middle lobe; RLL: right lower lobe; LUL: left upper lobe; LLL: left lower lobe. The effect size was presented with
Cohen’s d and Crémer’s V for student’s t-test and chi-squared test, respectively. *: indicates a 2-sided P value <0.05.

Perioperative PaO2 showed similar changes in both
groups but there were statistical differences between
them (P = 0.044, partial η2 = 0.026, Table 2). However,
the effect was small, and all measured values were in
clinically normal oxygenation level. pH and PaCO2 were
also statistically different between groups, all observed
values remained within clinically insignificant range, and
presented negligible effect size (P < 0.001, partial η2 =
0.083 for pH, P = 0.003, partial η2 = 0.057 for PaCO2).
4. Discussion
To our knowledge, this is the first study on the effect of
sugammadex on early postoperative CRA after single-port
VAT lobectomy carried out with profound neuromuscular
block. The incidence of CRA in the early postoperative
period decreased more with the use of sugammadex
than with pyridostigmine. Sugammadex resulted in
enhanced recovery from the profound neuromuscular
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block, facilitating active deep breathing immediately after
emergence from anesthesia; this might be beneficial in
preventing early postoperative atelectasis. The effects of
decreased incidence of CRA in the early postoperative
period were considerable with a small OR of 0.273
compared to using anticholinesterase. This was true even
when the patients with sugammadex received a higher
dose of NMBs. The patients also maintained adequate
respiration, not one patient presented significant CO2
retention postoperatively. Maintained normal PCO2 range
during the early postoperative period also refers indirectly
that patients have not experienced ventilation problems,
including pathologic bronchial obstruction from
secretions and inadequate respiratory muscle power [10].
Atelectasis is one of the most common postoperative
respiratory complications after thoracic surgery [18].
Atelectasis could be the cause of hypoxemia in the
early postoperative period and can be prevented with
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Table 2. Intraoperative and postoperative parameters.
Parameters

Group P (n = 69)

Group S (n = 90)

P value

Effect size

Amount of rocuronium (mg)

90.0 (70.0–107.5)

120.0 (100.0–140.0)

<0.001

0.55

Amount of pyridostigmine (mg/kg)

0.167 (0.153–0.189)

0 (0–0)

-

-

Amount of sugammadex (mg/kg)

0 (0–0)

2.08 (2.01–2.20)

-

-

N2O used during two-lung ventilation

39 (56.5)

63 (70.0)

0.079

0.14

N2O used during one-lung ventilation

6 (8.7)

8 (8.9)

0.966

0.00

Anaesthesia time (min)

245.0 (222.5–300.0)

225.0 (220.0–310.0)

0.535

0.05

Operation time (min)

180.0 (149.5–236.5)

186.5 (150.8–230.5)

0.999

0.00

One-lung ventilation time (min)

160 (130–202.5)

163 (132.5–215)

0.756

0.03

Extubation time (min)

8.0 (5.0–15.0)

7.0 (5.0–12.0)

0.266

0.20

Fluid administered (mL)

1050.0 (800.0–1337.5) 950.0 (700.0–1475.0)

0.769

0.02

Red blood cell transfusion

8 (11.6%)

6 (6.7%)

0.398

0.09

Expired tidal volume during two-lung ventilation (mL)

500 (500–600)

500 (450–550)

0.251

0.09

Respiratory rate during two-lung ventilation (cycles/min)

12 (12–12)

12 (12–13)

0.067

0.15

Expired tidal volume during OLV (mL)

339.6 ± 52.8

350.0 ± 60.8

0.223

0.20

Respiratory rate during OLV (cycles/min)

15 (15–16)

15 (15–16)

0.086

0.14

Maximal pain score

3.0 (3.0–5.0)

3.0 (3.0–4.0)

0.734

0.03

PONV

0.235

0.11

<0.001*

0.083

0.044*

0.026

0.003*

0.057

pH

PO2

PCO2

8 (11.6%)

4 (5.5%)

30 min after OLV

7.425 ± 0.052

7.446 ± 0.054

Immediate post operation

7.357 ± 0.039

7.381 ± 0.041

POD0 night

7.403 ± 0.053

7.408 ± 0.033

POD1 morning

7.407 ± 0.028

7.415 ± 0.027

30 min after OLV

203.6 ± 95.4

228.9 ± 104.8

Immediate post operation

149.6 ± 52.1

124.1 ± 39.3

POD0 night

183.6 ± 52.9

151 ± 49.9

POD1 morning

162 ± 47.4

142.3 ± 45.4

30 min after OLV

41.6 ± 9.4

38.5 ± 6.4

Immediate post operation

44.9 ± 5.9

42.3 ± 4.6

POD0 night

39.6 ± 5.4

39.7 ± 4.4

POD1 morning

39.9 ± 5.7

38.6 ± 5.4

*

Data are presented as median (IQR), mean ± SD, or number (percentile). Group P: patients who received pyridostigmine as the reversal
agent. Group S: patients who received sugammadex as the reversal agent. OLV: 1-lung ventilation; POD0: Postoperative day 0; POD1:
postoperative day 1; POD2: postoperative day 2. Extubation time measured from the anaesthetics-off to the time of endotracheal tube
extubation. The administered fluid volume present is the summed value of crystalloid and colloid, except the volume of blood products
used. The maximal units of transfused red blood cells were 3. Maximal pain score is maximal NRS pain score measured from POD0 to
POD2. PONV: number of patients with postoperative nausea and vomiting episode. The effect size was presented with a common effect
size r for Mann–Whitney U test and Crémer’s V for chi-squared or Fisher’s exact tests, partial η2 for one-way ANOVA with one repeated
factor. *: indicates a 2-sided P value <0.05.

several simple measures, including chest physiotherapy,
spontaneous deep breathing, and coughing. Copious
secretions, pain, and respiratory muscle weakness are
the common causes of atelectasis [19]. According to the
severity of atelectasis, various clinical symptoms such
as respiratory distress and hypoxemia could occur [20].

Atelectasis-induced respiratory distress and hypoxemia
usually develop immediately after emergence from general
anesthesia and could worsen until the postoperative day
(POD) 2 [21]. Subsegmental atelectasis could not be
associated with clinical symptoms from fever to hypoxemia
[22]; it is common after thoracic surgery and does not
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Table 3. Postoperative chest radiographic abnormalities.
Parameters

Group P
(n = 69)

Group S
(n = 90)

P value

Effect size

Chest radiographic changes on aeration

30 (43.5%)

24 (26.7%)

0.013*

0.35

Operated lung

18 (26.1%)

14 (15.6%)

Ventilated lung

7 (10.1%)

8 (8.9%)

0.359

0.14

Both lungs

1 (1.4%)

2 (2.2%)

Pleural effusion

29 (42.0%)

33 (36.7%)

0.245

0.11

Haemothorax

3 (4.3%)

0 (0.0%)

0.080

0.16

Pneumonia with overt symptoms and signs

0 (0.0%)

0 (0.0%)

-

-

Changes developed on

Data are expressed as the number of patients (percentile). Group P: patients who received pyridostigmine as the reversal
agent. Group S: patients who received sugammadex as the reversal agent. Postoperative pain was counted when the
measured score was over 3 using the numerical rating scale. Postoperative nausea and vomiting (PONV) were counted as
follows from the nursing care records and antiemetics administration history. *: indicates 2-sided P value < 0.05. Effect size:
Cohen’s h for z-test, Crémer’s V for chi-squared test and Fisher’s exact test.

Figure 2. The incidence of early postoperative chest radiographic abnormalities.
Numbers printed at the left side of each bar indicate the lung field where abnormalities
occurred; its legend is presented. *: 2-sided P < 0.050 with z-test. Incidence was 43.5%
vs. 26.7% for groups P and S, respectively, P = 0.013, Cohen’s h = 0.35. There was
no significant difference between groups on the lung fields where abnormalities
occurred (P = 0.359, Crémer’s V = 0.14, Fisher’s exact test).

respond to bronchoscope intervention [23]. To prevent
these pathologic problems, preoperative exercise and
postoperative respiratory rehabilitation, including deep
breathing, active coughing, and expectoration are essential
[24]. In our study, the use of sugammadex facilitated
deep breathing, coughing, and expectoration due to an
enhanced reversal of the effects of NMBs, thereby lowering
the incidence of CRA.

1242

Our results could be a preceding finding for other
positive prognostic outcomes of sugammadex use in
various surgical settings [25–27]. Compared to previous
reports on postoperative pulmonary complications [3,27],
we eliminated multiple factors that could have resulted
in postoperative respiratory complications, including
patients with moderate-grade systemic disease and those
who underwent complicated surgeries or intraoperative
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Table 4. The odds ratio of parameters related to the occurrence of early postoperative chest radiographic changes on aeration.
Univariate

Parameters (coding)

Multivariate

OR (95%CI)

P value

OR (95% CI)

P value

Group (sugammadex use)

0.209 (0.073–0.601)

0.004

0.273 (0.112–0.669)

0.005

Sex (female)

2.512 (0.865–7.294)

0.09

1.976 (0.753–5.186)

0.166

Age (years)

1.064 (1.000–1.132)

0.051

1.078 (1.021–1.137)

0.006

Body mass index (kg/m )

1.165 (1.010–1.345)

0.037

1.161 (1.017–1.324)

0.027

ASA classification (II)

2.327 (0.270–20.091)

0.442

-

-

Smoking (current)

2.603 (0.747–9.070)

0.133

2.811 (0.883–8.950)

0.080

Hypertension

0.338 (0.113–1.007)

0.051

0.401 (0.153–1.054)

0.064

Diabetes mellitus

1.429 (0.391–5.229)

0.59

-

-

Chronic lung disease

0.986 (0.136 – 7.158)

0.989

-

-

Preoperative cough

0.705 (0.151–3.282)

0.656

-

-

Preoperative dyspnoea

1.849 (0.360–9.505)

0.462

-

-

Preoperative dyspnoea

1.872 (0.168–20.872)

0.61

-

-

FVC%

0.992 (0.947–1.040)

0.749

-

-

FEV1%

1.002 (0.961 – 1.044)

0.931

-

-

DLCO%

1.030 (1.001–1.060)

0.046

1.025 (1.000– 1.051)

0.054

Intraoperative fluid administration (mL)

1.000 (0.999–1.001)

0.966

-

-

Allogenic red blood cell transfusion

2.452 (0.505–11.906)

0.266

-

-

Operation time (min)

0.999 (0.990–1.008)

0.806

-

-

PONV

0.111 (0.015–0.838)

0.033

0.189 (0.032–1.121)

0.067

Pain (over 3 NRS points)

0.532 (0.203–1.394)

0.199

-

-

Model summary

–2 Log likelihood = 135.70
Overall correct classification: 64.6%

2

–2 Log likelihood = 139.763
Overall correct classification: 67.7%

The exponential value of regression coefficients (odds ratio, OR) are presented with their 95% confidence intervals. Multivariate binary
logistic regression with backward stepwise selection method, tested with loglikelihood estimation. *: indicates a 2-sided P value <0.050.
Bootstrapped results are presented for multivariate analysis.

conversion to thoracotomy. Preoperative lung function in
both study groups was similar and not so compromised.
Intraoperative fluid management was based on minimal
volume administration, and both groups underwent
identical surgeries. Surgical and anesthesia times were
also similar in both groups. Intraoperative mechanical
ventilation was also performed according to the
standardized OLV management protocol. Also, VAT
lobectomy enhances early recovery [3] and the incidence
of respiratory complications in the early postoperative
period is between 15%–20% after VAT lobectomy [28]. In
this situation, decreased incidence of CRA in patients that
received sugammadex to reverse the effects of NMBs could
be a promising point. Patients with relatively low risk of
postoperative pulmonary complications could present
various CRA that are related to postoperative pulmonary

complications, and using sugammadex had the potential
of reducing pulmonary complication risk even when
the patients were compliant with pre and postoperative
treatment to prevent complications.
Dose-dependent prolonged NMB increases the risk of
postoperative respiratory complications [29]. In this study,
the major difference between the groups was the total
dose of rocuronium administered during anesthesia. In
group S, the anesthesiologists tended to use a more liberal
dose of rocuronium to induce profound neuromuscular
block until the end of the surgery, expecting rapid and
complete recovery from the neuromuscular block by
using sugammadex. The duration of anesthesia was not
different between groups, although a relatively large dose
of rocuronium was used in group S. This finding suggests
that sugammadex administration resulted in more rapid
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recovery from profound neuromuscular block compared
to pyridostigmine. The number of patients with diabetes
mellitus was higher in group S than in group P (5.8% vs.
20.0%, P = 0.011, Crémer’s V = 0.20). Diabetes mellitus
is a known single risk factor for postoperative pulmonary
complications [10]. Despite this finding, the incidence of
CRA was low in group S, and the estimated multivariate
logistic regression model did not include diabetes mellitus
as a significant independent factor.
In our study, 5 patients developed postoperative
pneumonic infiltration on chest radiography in the first 2
days after surgery. Among them, 4 patients had pneumonic
infiltrates preoperatively, suspected to be secondary to
cancer; all these lesions occurred at the operated lung
side without any presenting symptoms. Only 1 patient
had new-onset pneumonic infiltrates in the postoperative
period. This patient had a history of right-sided chest wall
trauma and recurrent pleural effusion. During the right
upper lobectomy, extensive pleurolysis was performed for
widespread pleural adhesions. Postoperatively, this patient
developed dyspnea and right-sided consolidation. On
POD 2, the bronchoscopic bronchial toilet was performed,
followed by antibiotic therapy for 1 month. Following this,
the patient was discharged without further complications.
Hemothorax occurred in 3 patients, all in group P; the
correlation coefficient with the use of sugammadex was
0.157, indicating a nonlinear relationship.
Our study has a number of limitations. First, the
development of respiratory complications was evaluated
only until POD 2. However, as the half-life of rocuronium
is 2 h, respiratory complications that occurred after
POD 2 may not be related to the use of NMB. Secondly,
sugammadex was introduced in our hospital in November
2013. Thus, most patients who underwent surgery after
November 2013 were included in group S. However, singleport VATS lobectomy had been in active use since 2012,
and the surgical technique was identical during the entire
study period [7]. Therefore, the bias related to the inclusion
of patients after November 2013 had minimal effect on the
final analysis. Instead, we limited the patients receiving
VAT lobectomy to between January 2013 and August 2015
only. By doing this, we could get a more homogenous
cohort. Thirdly, most parameters that are already known
as risk factors of postoperative pulmonary complications
were similar between the groups and not significant in the
multivariate logistic regression. In this study, most patients
with high risk were excluded and investigated about CRA
during early postoperative periods. These changes could
either progress to overt pulmonary complications or not
progress. It is an important finding that these changes
could be prevented effectively with sugammadex, even
in relatively healthy patients. Forth, the record about
positive end-expiratory pressure (PEEP) during 1-lung
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ventilation was not clear in our medical records. PEEP has
a considerable effect on atelectasis formation. Our hospital
is a training institution; we have a protocolized training
process for thoracic anesthesia, and in this protocol, the
stepwise recruitment procedure should be supplied to
all patients at the end of 1-lung ventilation. Uncertain
medical recordings about PEEP could be a significant bias
for our results; the recruitment performed at the end of
surgery could abolish this bias. Fifth, the records about
neuromuscular monitoring were not included in this study.
During the study period, we could not find a consistent
record of neuromuscular monitoring during anesthesia.
Presuming from our institutional practice at that time, 2
mg/kg sugammadex were administered after confirmation
of diaphragmatic movement; fortunately, we had not
experienced inadequate recovery from neuromuscular
blockade. No patient experienced postoperative hypoxemia
required for mechanical ventilation or reintubation. Only
1 patient who received relatively extensive surgery due to
previous trauma history suffered an unusual pulmonary
complication. These could be possible considering the
characteristics of included patients who were relatively
healthy without preoperative pulmonary problems. Even
in this population, sugammadex had superior effects on
developing early postoperative ventilation problems.
In conclusion, sugammadex use is associated with
a lower incidence of early postoperative CRA after
VAT lobectomy when compared to pyridostigmine.
Sugammadex enables rapid and complete reversal of
neuromuscular blockade via promoting active deep
breathing, coughing, and expectoration, which prevents
early postoperative ventilation abnormalities.
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